Drug Profile
Research programme: cytotoxic therapeutics - Supratek
Alternative Names: SP 1010C; SP 1010C-O; SP 1050C; SP 1051C; SP 1053C; SP 1060C-O; SP 5.210CLatest Information Update: 27 Feb 2023
Price :
$50
*
At a glance
- Originator Supratek Pharma
- Class Anthracyclines; Camptothecins; Paclitaxels; Taxanes; Tetrahydronaphthalenes
- Mechanism of Action DNA intercalators; DNA topoisomerase I inhibitors; RNA synthesis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 27 Feb 2023 Discontinued - Preclinical for Cancer in USA (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (PO)
- 28 Nov 2007 Research programme: cytotoxic therapeutics - Supratek is available for licensing as of 28 Nov 2007. http://www.supratek.com